Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis

Blood

Volumn 103, Issue 7, 2004, Pages 2727-2737

  Thieblemont, Catherine ^a   Nasser, Valéry ^b   Felman, Pascale ^b   Leroy, Karen ^b   Gazzo, Sophie ^b   Callet Bauchu, Evelyne ^b   Loriod, Béatrice ^b   Granjeaud, Samuel ^b   Gaulard, Philippe ^b   Haioun, Corinne ^b   Traverse Glehen, Alexandra ^b   Baseggio, Lucile ^b   Bertucci, François ^b   Birnbaum, Daniel ^b   Magrangeas, Florence ^b   Minvielle, Stéphane ^b   Avet Loiseau, Hervé ^b   Salles, Gilles ^b   Coiffier, Bertrand ^b   Berger, Françoise ^b   Houlgatte, Rémi ^b   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B;

ANGIOGENESIS; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL ADHESION; CELL CYCLE; CONTROLLED STUDY; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 12144288425     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2160     Document Type: Article

References (48)

1. Alizadeh A, Eisen M, Davis R, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:491-492.
2. Rosenwald A, Wright G, Chan W, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
3. Shipp M, Ross K, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
4. Shaffer A, Rosenwald A, Staudt L. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920-932.
5. Berger F, Felman P, Sonet A, et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood. 1994;83:2829-2835.
6. Rosenwald A, Alizadeh A, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
7. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
8. Klein U, Tu Y, Stolovitzky G, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
9. Jaffe E, Harris N, Stein H, Vardiman J. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001.
10. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95-103.
11. Uchimaru K, Taniguchi T, Yoshikawa M, et al. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11:14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood. 1997;89:965-974.
12. Traverse-Glehen A, Berger F, Davi F, et al. Analysis of VH genes in 48 marginal zone lymphoma cases reveals marked heterogeneity between splenic and nodal cases and suggest clonal selection [abstract]. Blood; 2002;100:568a.
13. Bertucci F, Houlgatte R, Benziane A, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet. 2000;9:2981-2991.
14. Bertucci F, Bernard K, Loriod B, et al. Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet. 1999;8:219-226.
15. Eisen M, Spellman P, Brown P, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
16. Golub T, Slonim D, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
17. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4998-5006.
18. Bland J, Altman D. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.
19. Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
20. Takahashi M, Rhodes D, Furge K, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98:9754-9759.
21. Schena M, Larsson L, Gottardi D, et al. Growth and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 1992;79:2981-2989.
22. Aguilar-Santelises M, Rottenberg M, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69:114-119.
23. Zaninoni A, Imperiali F, Pasquini C, Zanella A, Barcellini W. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol. 2003;31:185-190.
24. Punnonen J, Aversa G, Cocks B, de Vries J. Role of interleukin-4 and interleukin-13 in synthesis of IgE and expression of CD23 by human B cells. Allergy. 1994;49:576-586.
25. Thieblemont C, Chettab K, Felman P, et al. Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia. 2002;16:2326-2329.
26. Vivanco I, Sawyers C. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;7:489-501.
27. Tanaka M, Adzuma K, Iwami M, Yoshimoto K, Monden Y, Itakura M. Human calgizzarin: one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. Cancer Lett. 1995;89:195-200.
28. Tomasetto C, Regnier C, Moog-Lutz C, et al. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics. 1995;28:367-376.
29. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003;63:140-148.
30. Neeper M, Schmidt A, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
31. Hofmann M, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
32. Lander H, Tauras J, Ogiste J, Hori O, Moss R, Schmidt A. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
33. Huttunen H, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;274:19919-19924.
34. Swendeman S, Spielholz C, Jenkins N, Gilbert D, Copeland N, Sheffery M. Characterization of the genomic structure, chromosomal location, promoter, and development expression of the alpha-globin transcription factor CP2. J Biol Chem. 1994;269:11663-11671.
35. Hofmann W, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98:787-794.
36. de Vos S, Krug U, Hofmann W, et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol. 2003;12:35-43.
37. Laisney V, Nguyen Van C, Gross M, Frezal J. Human genes for glutathione S-transferases. Hum Genet. 1984;68:221-227.
38. Ribrag V, Fadel I, Cebotaru C, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas [abstract]. Blood. 1999;94:65a.
39. Batista I, Romaguera J, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol. 2001;2:141-148.
40. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 1998;12:1281-1287.
41. Gupta D, Lim M, Medeiros L, Elenitoba-Johnson K. Small lymphocytic lymphoma with perifollicular, marginal zone, or interfollicular distribution. Mod Pathol. 2000;13:1161-1166.
42. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85:487-491.
43. Jadayel D, Matutes E, Dyer M, et al. Splenic lymphoma with villous lymphocytes: analysis of bcl-1 rearrangements and expression of the cyclin D1 gene. Blood. 1994;83:3664-3671.
44. Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Francais d'Hematologie Cellulaire (GFHC) study. Br J Haematol. 1998;101:712-721.
45. Brito-Babapulle V, Ellis J, Matutes E, et al. Translocation t(11-14)(q13-q32) in chronic lymphoid disorders. Genes Chromosomes Cancer. 1992;5:158-165.
46. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253-2261.
47. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 2001;15:1262-1267.
48. Wu E, Aguiar R, Savage K, et al. PKCb: a rational therapeutic target in diffuse large B-cell lymphoma [abstract]. Blood. 2002;100:202a.